Metabolic syndrome (MetS) is often implicated in atherosclerosis (ASVD) and cardiovascular (CV) diseases. This condition often affects patients with certain rheumatic diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and other chronic inflammatory diseases. Therefore, understanding the link between these diseases and their respective treatments is paramount.
Our goal is to enhance our knowledge concerning this topic and comprehend to what extent the inflammatory process responsible for atherosclerosis is affected by drugs intended for rheumatic diseases. At the same time, uncovering how metabolic changes in patients with rheumatic diseases impact the inflammatory process represents a crucial area of investigation.
Chronic inflammatory conditions pose an independent risk factor for cardiovascular diseases. As such, the associated treatments often hasten atherosclerotic disease induced by vascular wall inflammation, accompanied by changes in the cholesterol composition, both qualitatively and quantitatively.
Steroid therapy, a commonly employed treatment for autoimmune conditions, is also a potential culprit in elevating serum glucose and lipid levels. Furthermore, it is worth noting that a pathophysiological process typically involving critical organs such as the kidneys, heart, and lungs, could lead to a deterioration that inevitably affects cardiovascular functions. Steroidal and non-steroidal anti-inflammatory drug (NSAID) therapies may significantly affect cardiovascular activity due to their pharmacodynamic properties.
Though metabolic syndrome has been thoroughly researched as a standalone condition, definitive research connecting it with systemic autoimmune diseases lacks comprehensive exploration. Expanding knowledge in this area could lead to the development of more precise therapies and preventive measures for patients affected by these conditions.
Given their potential impact on cardiovascular health, systemic autoimmune should be integral components of cardiovascular risk calculation, enabling healthcare providers to offer precise predictions and devise comprehensive prevention or treatment protocols.
We encourage researchers to submit Original Research, Reviews, Brief Research Reports, Case Reports, Clinical Trials, General Commentary, Hypothesis & Theory, Methods, Mini Review, Perspective, Study Protocol, Systematic Review articles pertinent to this Research Topic. Potential topics of interest include, but are not limited to:
• Cardiovascular risk factors in systemic autoimmune diseases and risk reduction strategies.
• Identification of biomarkers linked with elevated cardiovascular risk.
• Direct effects of systemic autoimmune diseases on cardiovascular health.
• Impacts of metabolic modifications in patients with rheumatic on the inflammatory process.
• Evaluation of treatment options for rheumatic diseases: Comparative risk-benefit analyses.
• Comprehensive reviews on steroid therapy's effects on glucose and lipid levels.
• Investigation into the pharmacodynamic impacts of steroidal and NSAID therapies on metabolic syndrome.
• Implications of metabolic syndrome on vital organ pathophysiology.
• Case studies detailing accelerated atherosclerosis due to anti-inflammatory treatments.
• The role of cholesterol composition variations in rheumatic diseases progression.
• Potential predictors of cardiovascular diseases in patients with systemic autoimmune conditions.
• Correlation between metabolic syndrome, rheumatic diseases, and cardiovascular diseases.
• Exploration and development of potential preventive measures for reducing cardiovascular risk in patients with rheumatic and autoimmune conditions.
Metabolic syndrome (MetS) is often implicated in atherosclerosis (ASVD) and cardiovascular (CV) diseases. This condition often affects patients with certain rheumatic diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and other chronic inflammatory diseases. Therefore, understanding the link between these diseases and their respective treatments is paramount.
Our goal is to enhance our knowledge concerning this topic and comprehend to what extent the inflammatory process responsible for atherosclerosis is affected by drugs intended for rheumatic diseases. At the same time, uncovering how metabolic changes in patients with rheumatic diseases impact the inflammatory process represents a crucial area of investigation.
Chronic inflammatory conditions pose an independent risk factor for cardiovascular diseases. As such, the associated treatments often hasten atherosclerotic disease induced by vascular wall inflammation, accompanied by changes in the cholesterol composition, both qualitatively and quantitatively.
Steroid therapy, a commonly employed treatment for autoimmune conditions, is also a potential culprit in elevating serum glucose and lipid levels. Furthermore, it is worth noting that a pathophysiological process typically involving critical organs such as the kidneys, heart, and lungs, could lead to a deterioration that inevitably affects cardiovascular functions. Steroidal and non-steroidal anti-inflammatory drug (NSAID) therapies may significantly affect cardiovascular activity due to their pharmacodynamic properties.
Though metabolic syndrome has been thoroughly researched as a standalone condition, definitive research connecting it with systemic autoimmune diseases lacks comprehensive exploration. Expanding knowledge in this area could lead to the development of more precise therapies and preventive measures for patients affected by these conditions.
Given their potential impact on cardiovascular health, systemic autoimmune should be integral components of cardiovascular risk calculation, enabling healthcare providers to offer precise predictions and devise comprehensive prevention or treatment protocols.
We encourage researchers to submit Original Research, Reviews, Brief Research Reports, Case Reports, Clinical Trials, General Commentary, Hypothesis & Theory, Methods, Mini Review, Perspective, Study Protocol, Systematic Review articles pertinent to this Research Topic. Potential topics of interest include, but are not limited to:
• Cardiovascular risk factors in systemic autoimmune diseases and risk reduction strategies.
• Identification of biomarkers linked with elevated cardiovascular risk.
• Direct effects of systemic autoimmune diseases on cardiovascular health.
• Impacts of metabolic modifications in patients with rheumatic on the inflammatory process.
• Evaluation of treatment options for rheumatic diseases: Comparative risk-benefit analyses.
• Comprehensive reviews on steroid therapy's effects on glucose and lipid levels.
• Investigation into the pharmacodynamic impacts of steroidal and NSAID therapies on metabolic syndrome.
• Implications of metabolic syndrome on vital organ pathophysiology.
• Case studies detailing accelerated atherosclerosis due to anti-inflammatory treatments.
• The role of cholesterol composition variations in rheumatic diseases progression.
• Potential predictors of cardiovascular diseases in patients with systemic autoimmune conditions.
• Correlation between metabolic syndrome, rheumatic diseases, and cardiovascular diseases.
• Exploration and development of potential preventive measures for reducing cardiovascular risk in patients with rheumatic and autoimmune conditions.